Track OVID and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$200.10M
Enterprise Value$131.89M
Revenue (TTM)$7.25M
Net Income (TTM)-$17.41M
Free Cash Flow (TTM)-$38.33M
Financial Health
Cash$69.64M
Net Debt-$68.20M
Debt Ratio0.01
Debt to Equity0.01
Interest Coverage-
Valuation (TTM)
Price to Sales27.59
Price to Earnings-11.49
EV to EBITDA-3.15
Price to Book1.53
Price to Free Cash Flow-5.22
Margins (TTM)
Gross Profit Margin99.16%
EBITDA Margin-576.63%
Operating Income Margin-585.20%
Net Income Margin-240.11%
Free Cash Flow Margin-528.60%
Returns (5Y Avg)
Return on Invested Capital-25.19%
Return on Assets-21.44%
Return on Equity-16.44%
Return on Total Capital-25.19%
Return on Capital Employed-23.73%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-10.48%
Diluted EPS15.42%
Total Debt1000.00%
Capital Expenditures-92.39%
Free Cash Flow31.42%
CAGR (3Y)
Revenue68.99%
Diluted EPS14.74%
Total Debt38.97%
Capital Expenditures-99.11%
Free Cash Flow1000.00%
CAGR (1Y)
Revenue1000.00%
Diluted EPS15.90%
Total Debt7.26%
Capital Expenditures-100.00%
Free Cash Flow1000.00%
$2.41+$0.11|+4.36%
Last updated: Jul 21, 4:00 PM ET
52W High$3.10
52W Low$0.47
50D SMA$2.51
200D SMA$2.00
Volume1.77M
Ovid Therapeutics Inc
Hudson Commons, New York, NY, United States, 10001
IPO
2017
Employees
23
Industry
Biotechnology
Sector
Healthcare
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20250+1
1
Q1 20240+1
1
2-quarter cumulative
0 sells2 buys
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0